Sign up
Pharma Capital

Wellesley Pharmaceuticals looks to raise $10 million for next round of clinical trials

Wellesley Pharmaceuticals CEO David Dill tells Proactive Investors the privately held company is aiming to treat the frequent need to urinate at night with its drug Nocturol. 

Dill says after the company received "compelling" data from its Phase 2 trials, it's hopeful to sign a licensing agreement with a big pharma to take over its drug. In the meantime, the company is raising capital to fund its next round of trials.

 

View full WELLE profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.